The stock of Trevi Therapeutics Inc (TRVI) has gone down by -7.88% for the week, with a 42.94% rise in the past month and a 42.60% rise in the past quarter. The volatility ratio for the week is 5.16%, and the volatility levels for the past 30 days are 7.65% for TRVI. The simple moving average for the past 20 days is -0.64% for TRVI’s stock, with a 69.76% simple moving average for the past 200 days.
Is It Worth Investing in Trevi Therapeutics Inc (NASDAQ: TRVI) Right Now?
The 36-month beta value for TRVI is at 0.41. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRVI is 57.14M, and currently, shorts hold a 8.19% of that float. The average trading volume for TRVI on April 01, 2025 was 1.97M shares.
TRVI) stock’s latest price update
Trevi Therapeutics Inc (NASDAQ: TRVI)’s stock price has gone decline by -3.19 in comparison to its previous close of 6.29, however, the company has experienced a -7.88% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-03-18 that Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good – Co-Founder, President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Conference Call Participants Faisal Khurshid – Leerink Partners Mayank Mamtani – B. Riley Annabel Samimy – Stifel Leland Gershell – Oppenheimer Serge Belanger – Needham & Company Ryan Deschner – Raymond James Brandon Folkes – Rodman & Renshaw Christian Cubides – Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with Raymond James repeating the rating for TRVI by listing it as a “Strong Buy.” The predicted price for TRVI in the upcoming period, according to Raymond James is $29 based on the research report published on March 10, 2025 of the current year 2025.
Needham, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $25, previously predicting the price at $8. The rating they have provided for TRVI stocks is “Buy” according to the report published on March 10th, 2025.
H.C. Wainwright gave a rating of “Buy” to TRVI, setting the target price at $7.50 in the report published on December 12th of the previous year.
TRVI Trading at 22.85% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.60% of loss for the given period.
Volatility was left at 7.65%, however, over the last 30 days, the volatility rate increased by 5.16%, as shares surge +35.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.11% upper at present.
During the last 5 trading sessions, TRVI fell by -8.93%, which changed the moving average for the period of 200-days by +111.97% in comparison to the 20-day moving average, which settled at $6.12. In addition, Trevi Therapeutics Inc saw 47.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from SCIASCIA THOMAS, who sale 2,631 shares at the price of $6.60 back on Mar 25 ’25. After this action, SCIASCIA THOMAS now owns 221,373 shares of Trevi Therapeutics Inc, valued at $17,365 using the latest closing price.
GOOD JENNIFER L, the President & CEO of Trevi Therapeutics Inc, sale 5,263 shares at $6.58 during a trade that took place back on Mar 21 ’25, which means that GOOD JENNIFER L is holding 213,313 shares at $34,625 based on the most recent closing price.
Stock Fundamentals for TRVI
The total capital return value is set at -0.51. Equity return is now at value -52.59, with -47.84 for asset returns.
Based on Trevi Therapeutics Inc (TRVI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -37.07. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -12881.25.
Currently, EBITDA for the company is -51.52 million with net debt to EBITDA at 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.41.
Conclusion
In conclusion, Trevi Therapeutics Inc (TRVI) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
